Does Tesamorelin Burn Belly Fat? The Label Calls It Weight Neutral

Tesamorelin reduces visceral fat, the deep fat packed around the organs. The label of the approved product, Egrifta, calls the drug weight neutral, in the same sentence that rules out weight management. Both things are true at once, and the gap between them is where the marketing lives. One trial gave it to people without HIV for a year. Subcutaneous fat, the layer you can pinch, did not move.

Does tesamorelin burn belly fat?

Tesamorelin reduces one kind of belly fat and leaves the other alone. Across the two phase 3 trials behind the approval, visceral adipose tissue fell 18% in one study and 14% in the other, against a 2% rise and a 2% fall on placebo.¹ In a separate 12-month trial in people without HIV, abdominal subcutaneous fat showed "no significant effects," with a p value of 0.40.²

Those two facts answer different questions. Deep fat responds. The layer under the skin is the one most people mean by belly fat. It did not move.

Scale matters here too. A 27 cm² reduction shows up clearly on a cross-sectional scan. On a waistline it barely registers, and the trials were not built to photograph anybody.

What is Egrifta approved for, and what does the label rule out?

Egrifta is approved for excess abdominal fat in one population: adults with HIV-related lipodystrophy. Both the current and the previous formulation carry the same sentence: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy."³ Lipodystrophy here means a fat redistribution syndrome seen in people on long-term antiretroviral therapy, where fat leaves the limbs and face and accumulates in the abdomen.

Nothing in that sentence covers general abdominal obesity. No regulator has approved tesamorelin for it.

What the label rules out

The same label section rules out the use people want it for, three times over, in stronger terms than most summaries report. The limitations of use state that "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect."³ The opening summary shortens it to "Not indicated for weight loss management," and the patient information repeats it as "EGRIFTA WR is not for weight loss management."³

The operative phrase is weight neutral. A drug can move fat between compartments without changing the number on a scale. The manufacturer put that in its own label.

How much visceral fat did the trials actually remove?

The trials removed between 14% and 18% of visceral fat, depending on which of the two you read. Study 1 randomized 412 patients and Study 2 randomized 404, each with a 26-week main phase.¹ Visceral adipose tissue fell 27 cm² on drug against a 4 cm² rise on placebo in Study 1, a treatment difference of "-31 cm² (95% CI -39, -24)" or 20 percentage points.¹ Study 2 showed a 21 cm² fall against no change, a difference of "-21 cm² (95% CI -29, -12)" or 12 percentage points.¹

Trunk fat fell 1.0 kg in Study 1 and 0.8 kg in Study 2 over the same 26 weeks.¹ A kilogram of trunk fat is a real change and it is not a visible one.

Why does the published figure differ from the label figure?

A 15.2% reduction circulates widely and matches neither study on the label. Secondary coverage of tesamorelin, including our own comparison of the four growth hormone secretagogues, reports visceral fat down 15.2% against a 5.0% rise on placebo at p less than 0.001. Section 14 reports 18% against a 2% rise, and 14% against a 2% fall.¹

I have not read the publication that produced 15.2% and 5.0% at source, so I cannot say which analysis population generated it. Published trial reports and label tables routinely differ because they use different sets: completers against intention to treat, or a pooled analysis against two separate ones. What can be said is which citation is stronger for a reader. The label figures went through FDA review of the raw submission, they are attached to named studies with participant counts, and they carry confidence intervals. The 15.2% figure, as it appears in secondary sources, carries none of that. This page uses the label.

Did anyone lose weight?

Barely. Body weight moved less than half a kilogram in either direction. The weight neutral language is built on that. Study 1 recorded a 0.4 kg fall on drug against no change on placebo, and Study 2 recorded a 0.5 kg rise against a 0.3 kg rise.¹ The label describes the drug arm difference as not statistically meaningful.¹

A third trial points the same way. In the 50-patient trial that measured liver fat, the treatment effect on body mass index carried a p value of 0.89, about as close to no signal as a number gets.⁴

Anyone expecting the scale to respond is expecting something three separate trials did not produce.

What happened in people without HIV?

In people without HIV, visceral fat fell too, in the one randomized trial that has looked. That makes it the most relevant evidence for anybody outside the approved indication. Makimura and colleagues gave tesamorelin 2 mg daily or placebo to "60 abdominally obese subjects with reduced GH secretion" for 12 months.² Visceral adipose tissue changed by "-16 ± 9 vs.19 ± 9 cm2", a treatment effect of "-35 (-58, -12) cm2; P = 0.003".²

So the visceral effect does appear outside HIV lipodystrophy, at a magnitude in the same range as the approval trials, over twice the duration. Two caveats sit on that result. The participants were selected for reduced growth hormone secretion, a narrower group than the general population of people with abdominal fat, and 60 participants is a small trial by the standards of anything sold on the strength of it.

Other things moved in that trial besides fat. Triglycerides, C-reactive protein and carotid intima-media thickness all improved, and fasting glucose, 2-hour glucose and glycated hemoglobin did not change.² Carotid intima-media thickness is a measurement of arterial wall thickening used as a stand-in for cardiovascular risk, so an improvement in it is a promising surrogate and not an outcome. Nobody has counted cardiovascular events on this drug, and the label still says long-term cardiovascular safety is not established.³

Did subcutaneous fat change?

Subcutaneous fat did not change. The same 12-month trial reported "no significant effects on abdominal sc adipose tissue" at "P = 0.40".² A p value of 0.40 is not a borderline miss. It is the result you get when nothing happened.

That result separates what tesamorelin does from what people buy it for. Visceral fat sits behind the abdominal wall and does not change the silhouette much. Subcutaneous fat is the layer that does. Over a year, it did not respond.

The selectivity is not a flaw in the drug, and it is the whole basis of the approved indication. HIV-associated lipodystrophy is a redistribution problem: fat leaves the face and limbs and collects in the abdomen, so a drug that pulls down the visceral compartment without touching subcutaneous stores is treating the thing that went wrong. In general abdominal obesity, that same selectivity is why the appearance changes so little.

What happened to liver fat?

Liver fat fell modestly in the one trial that measured it directly. Stanley and colleagues randomized 50 patients with HIV and abdominal fat accumulation to tesamorelin or placebo for 6 months.⁴ Median liver fat, as a lipid to water percentage, changed by "-2.0% [interquartile range {IQR}, -6.4% to 0.1%]" on drug against "0.9% [IQR, -0.6% to 3.7%]" on placebo, p equal to 0.003.⁴ Visceral fat in the same trial fell 34 cm² against an 8 cm² rise, a treatment effect of "-42 cm2 [95% CI, -71 to -14 cm2]; P = .005".⁴

The authors call the liver change modest themselves and say further studies are needed to establish its clinical importance.⁴ That is a more cautious reading than most summaries of this trial give it.

What happens when you stop?

Stopping brings the visceral fat back, and the extension phases put a number on how fast. Both phase 3 studies ran a 26-week extension in which some patients continued and others switched to placebo. Among those who continued, mean visceral fat change across weeks 26 to 52 was 0% in Study 1 and a 5% fall in Study 2. Among those switched to placebo, it rose 22% and 16%.¹

Six months of accumulated effect reversed inside six months of stopping. One detail in the design matters: those patients had already been on the drug for 26 weeks, so the 22% and 16% rises are a rebound from a reduced baseline rather than ordinary fat gain in untreated people.

Any claim about tesamorelin and body composition that leaves this out is describing a treatment as though it were a cure.

What does it do to IGF-1?

IGF-1 goes up, often past the range anyone would call normal. Among patients treated for 26 weeks, "47% had IGF-1 levels greater than 2 standard deviation scores (SDS)," and "36% had SDS >3, with this effect seen as early as 13 weeks of treatment."³ At 52 weeks the figures were 34% above 2 SDS and 23% above 3 SDS.³ In the non-HIV trial, IGF-1 rose by 92 µg/liter against placebo, p less than 0.0001.²

The label's instruction follows from that: "Monitor IGF-1 levels during EGRIFTA WR therapy" and "Consider discontinuing EGRIFTA WR in patients with persistent elevations of IGF-1 levels (e.g., >3 SDS)," particularly where the "efficacy response is not robust."³ It also states plainly that "The effects of prolonged elevations in IGF-1 levels are unknown."³ Our guide to what bloodwork to run before and after covers what an SDS is and why a raw IGF-1 number without an age reference tells you very little.

Do people develop antibodies to it?

Antibodies turn up in about half of patients, and they do not appear to stop the drug working. Section 12.6 records that "anti-tesamorelin IgG antibodies were detected in 50% of patients who received EGRIFTA for 26 weeks" and in 47% of those treated for 52 weeks.³ Among patients who had a hypersensitivity reaction, 85% had antibodies.³

Two details in that section are more interesting than the headline figure. Cross-reactivity to the body's own growth hormone releasing hormone "was observed in approximately 60%" of patients who developed antibodies, meaning the immune response does not reliably distinguish the drug from the hormone it imitates.³ Neutralizing antibodies appeared in vitro at week 52 in 10% of patients against tesamorelin and 5% against human GHRH.³

Despite all of that, section 12.6 states that "Patients with and without anti-tesamorelin IgG antibodies had similar mean reductions in visceral adipose tissue" and IGF-1 response, and that changes were comparable with or without neutralizing antibodies.³ Antibody status also fades: of those positive at 26 weeks, 18% were still positive six months after stopping.³

What are the side effects, and who does the label exclude?

The side effects on the label are led by injection site reactions, and the joint and nerve complaints behind them are the signature of raised growth hormone. Arthralgia, injection site erythema and injection site pruritus are the reactions reported in more than 5% of patients, with pain in extremity, peripheral edema and myalgia also listed.³ Section 5.6 puts the incidence of injection site reactions at "25% in EGRIFTA treated patients and 14% in placebo-treated patients" over the first 26 weeks.³

Joint pain, swelling, carpal tunnel syndrome and peripheral edema are what growth hormone excess looks like in a clinic, and they sit on this label alongside an instruction to monitor IGF-1. The individual placebo comparisons in the adverse reaction table could not be read reliably through the data route used here, because the table collapses into a single text field, so no per-reaction percentage pair from that table is quoted on this page.

On exclusions, the wording is blunt. Section 5.1 instructs prescribers to "Do not treat patients with active malignancy with EGRIFTA WR" and to "Discontinue EGRIFTA WR if there is any evidence of recurrent malignancy."³ The same reasoning sits behind the IGF-1 monitoring instruction: a growth factor elevated for a long time has effects the prescribing information calls unknown.

Does it affect blood sugar?

Blood sugar is where the two sources here disagree. The larger one is the cautious one. Section 5.4 states that "An increased risk of developing diabetes with EGRIFTA (HbA 1c level ≥ 6.5%) relative to placebo was observed" and instructs prescribers to evaluate glucose status before starting.³ The 12-month trial in people without HIV found "no changes in fasting, 2-h glucose, or glycated hemoglobin".²

The label's signal comes from the pooled phase 3 population of more than 800 patients. The null result comes from 60. A trial of 60 people over a year is not powered to rule out a glucose effect that a trial of 800 detected, so the disagreement is better read as absence of evidence in the smaller study than as evidence of absence. Growth hormone raises insulin resistance by a known mechanism, so the label's direction is the one to plan around.

Was the approved product itself ever tested for fat loss?

The product on sale today was never tested for fat reduction itself. The efficacy tables in the current document come from the original 2 mg formulation, and the prescribing information puts the 1.28 mg EGRIFTA WR dose at comparable systemic exposure to it. It does not report visceral fat results for EGRIFTA WR itself.³

That is an ordinary regulatory path. A reformulation that achieves the same blood levels as a product with established efficacy can be approved on that bridge instead of a fresh outcome trial. It also means the fat reduction figures quoted for the product on sale today were measured on a different formulation. For the current one, the only thing shown is that it reaches similar concentrations.

What has not been measured?

No trial has tested tesamorelin in people with abdominal obesity and normal growth hormone secretion. The 12-month trial selected for reduced secretion and the approval trials selected for HIV lipodystrophy, so the population buying it in the largest numbers is the one nobody has studied.²¹

Clinical outcomes are the second gap. Every figure on this page is a compartment measurement or a lab value. Carotid intima-media thickness improved in the 12-month trial, and that measure is a surrogate for cardiovascular risk, not an event count. The label still says long-term cardiovascular safety is not established.²³

Duration is the third. The longest randomized data runs 12 months. Our guide to why most peptides have no human evidence covers why that ceiling is the normal condition in this category, and tesamorelin is the compound in the growth hormone group with the most evidence, not the least.

Common questions

Does tesamorelin burn belly fat?

Is tesamorelin approved for weight loss?

What is Egrifta actually approved for?

How much visceral fat does it remove?

Does tesamorelin work in people without HIV?

Will I lose weight on tesamorelin?

Does the fat come back if you stop?

Does tesamorelin reduce liver fat?

How high does tesamorelin push IGF-1?

Does tesamorelin affect blood sugar?

Who should not take tesamorelin?

Is tesamorelin the same as Egrifta?

Was EGRIFTA WR itself tested for fat reduction?

Why do some sources say 15.2% instead of 18%?

Do people develop antibodies to tesamorelin?

What are the most common tesamorelin side effects?

Does tesamorelin build muscle?

Is tesamorelin banned in sport?

How long is the longest tesamorelin trial?

Sources

1. EGRIFTA SV (tesamorelin for injection), US prescribing information, sections 1, 5.1, 5.2, 5.4 and 14, including Table 2 (visceral adipose tissue, main phase), Table 3 (body weight) and Table 4 (extension phase). Read at source via the openFDA drug label API (https://api.fda.gov/drug/label.json), indications_and_usage, warnings_and_precautions and clinical_studies fields, 30 October 2026. The two studies are identified on the label as NCT 00123253 and NCT 00435136. Quoted for every visceral adipose tissue, trunk fat, body weight and extension figure on this page. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18
2. Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK. Metabolic Effects of a Growth Hormone-Releasing Factor in Obese Subjects with Reduced Growth Hormone Secretion: A Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism 2012;97(12):4769-4779. DOI 10.1210/jc.2012-2794. Abstract read at source; full text paywalled. Quoted for the 60 participants, the 12-month duration, the visceral adipose tissue treatment effect, the subcutaneous fat p value of 0.40, the IGF-1 increase and the glucose result. The body weight change is not reported in the abstract and is therefore not quoted here. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14
3. EGRIFTA WR (tesamorelin) kit, US prescribing information, Theratechnologies Inc., sections 1, 5.1, 5.2, 5.4, 14 and the patient information. Printed revision date 3/2025. Read at source via DailyMed, label Set ID 839334d3-8c1d-4c26-9036-2ab524a6ea75, 30 October 2026. Quoted for the indication, all three weight management statements, the IGF-1 SDS figures and monitoring instruction, the malignancy instruction, the cardiovascular limitation, the diabetes risk statement and the comparable systemic exposure statement for the 1.28 mg dose. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33
4. Stanley TL, Feldpausch MN, Oh J, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA 2014;312(4):380-389. DOI 10.1001/jama.2014.8334. Read at source, 30 October 2026; the page carries institutional access prompts but the results section and figures were readable. Quoted for the 50 participants, the 6-month duration, the liver fat medians and interquartile ranges, the visceral fat treatment effect and the authors' own description of the liver change as modest. Body weight and IGF-1 change are not reported in the readable portion and are therefore not quoted. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8